1.
op Bruinink DH, Oliva S, Rihova L, Schmitz A, Gilestro M, te Marvelde J, Kralova R, Høholt H, Broijl A, Johnsen HE, Hajek R, Boccadoro M, Sonneveld P, Omedè P, van der Velden VH. Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network. Haematologica 2020;106(5):1496-1499; https://doi.org/10.3324/haematol.2020.267831.